LH

Labcorp Holdings Inc

Add to Watchlist

Advanced Chart

267.670

+1.82(0.685%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

268.590

Open

266.780

VWAP

267.68

Vol

522.30K

Mkt Cap

22.24B

Low

266.780

Amount

139.81M

EV/EBITDA(TTM)

12.91

Total Shares

84.29M

27.11B

EV/OCF(TTM)

16.01

P/S(TTM)

1.66

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

3.56B

+8.39%

4.126

+17.89%

3.58B

+7.43%

3.975

+15.22%

3.51B

+5.01%

4.096

+6.66%

Estimates Revision

The market is revising Upward the revenue expectations for Labcorp Holdings Inc. (LH) for FY2025, with the revenue forecasts being adjusted by 0.77% over the past three months. During the same period, the stock price has changed by 6.67%.

Revenue Estimates for FY2025

Revise Upward

+0.77%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.24%

In Past 3 Month

Stock Price

Go Up

+6.67%

In Past 3 Month

15 Analyst Rating

10.77% Upside

Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 296.50 USD with a low forecast of 260.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

3 Hold

0 Sell

Strong Buy

10.77% Upside

Current: 267.670

Low

260.00

Averages

296.50

High

325.00

10.77% Upside

Current: 267.670

Low

260.00

Averages

296.50

High

325.00

Morgan Stanley

Overweight

maintain

$283 -> $306

2025-07-25

Reason

Morgan Stanley

Price Target

$283 -> $306

2025-07-25

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Labcorp to $306 from $283 and keeps an Overweight rating on the shares. Organic volume growth and "impressive" Biopharma experience buoyed shares despite high expectations into the earnings report, the analyst noted. Heightened utilization expectations are "encouraging" into the second half, the analyst added in a post-earnings note.

Baird

NULL

Outperform

maintain

$290 -> $302

2025-07-25

Reason

Baird

Price Target

$290 -> $302

2025-07-25

maintain

NULL

Outperform

Reason

Baird raised the firm's price target on Labcorp to $302 from $290 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.

Truist

Buy

maintain

$290 -> $310

2025-07-25

Reason

Truist

Price Target

$290 -> $310

2025-07-25

maintain

Buy

Reason

Truist raised the firm's price target on Labcorp to $310 from $290 and keeps a Buy rating on the shares. Truist remains bullish on Labcorp following Q2 results that featured beats on the top and bottom lines, solid trends across segments with operating margin expansion and raised FY guidance, the analyst tells investors in a research note. Financial flexibility remains attractive, supporting execution on the pipeline and return of value to shareholders, the firm adds.

UBS

Kevin Caliendo

maintain

$282 -> $305

2025-07-25

Reason

UBS

Kevin Caliendo

Price Target

$282 -> $305

2025-07-25

maintain

Reason

UBS analyst Kevin Caliendo raised the firm's price target on Labcorp to $305 from $282 and keeps a Buy rating on the shares.

Evercore ISI

Elizabeth Anderson

Outperform

maintain

$285 -> $300

2025-07-24

Reason

Evercore ISI

Elizabeth Anderson

Price Target

$285 -> $300

2025-07-24

maintain

Outperform

Reason

Evercore ISI analyst Elizabeth Anderson raised the firm's price target on Labcorp to $300 from $285 and keeps an Outperform rating on the shares following what the firm called a "solid" Q2 report. The firm is raising its 2025 EPS estimate to $16.41 from $16.09, citing continuing strong utilization trends, share gains and strong specialty growth in diagnostics, among other factors.

Jefferies

Buy

maintain

$290 -> $300

2025-07-24

Reason

Jefferies

Price Target

$290 -> $300

2025-07-24

maintain

Buy

Reason

Jefferies raised the firm's price target on Labcorp to $300 from $290 and keeps a Buy rating on the shares. The company delivered a solid beat and raise quarter, with the Bioanalytical Lab Solutions & Services beat and backlog an encouraging sign for its Endocrine Disruptor moving forward, the analyst tells investors in a research note. The firm added that while the guidance raise was driven by foreign exchange, it continues to like the setup.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Labcorp Holdings Inc (LH.N) is 15.94, compared to its 5-year average forward P/E of 14.06. For a more detailed relative valuation and DCF analysis to assess Labcorp Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

14.06

Current PE

15.94

Overvalued PE

16.44

Undervalued PE

11.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

10.38

Current EV/EBITDA

11.34

Overvalued EV/EBITDA

11.84

Undervalued EV/EBITDA

8.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.54

Current PS

1.54

Overvalued PS

1.75

Undervalued PS

1.33

Financials

Annual

Quarterly

FY2025Q2

YoY :

+9.51%

3.53B

Total Revenue

FY2025Q2

YoY :

+30.09%

398.60M

Operating Profit

FY2025Q2

YoY :

+15.90%

238.30M

Net Income after Tax

FY2025Q2

YoY :

+16.39%

2.84

EPS - Diluted

FY2025Q2

YoY :

+25.36%

542.70M

Free Cash Flow

FY2025Q2

YoY :

+3.32%

27.72

Gross Profit Margin - %

FY2025Q2

YoY :

+5.96%

6.76

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 328.71% over the last month.

Sold

0-3

Months

3.3M

USD

3-6

Months

3.1M

USD

6-9

Months

6.8M

USD

0-12

Months

2.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 676.52% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

92.5K

Volume

6-9

Months

11.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

58.4K

Volume

Months

6-9

35.9K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.0K

USD

3-6

Months

24.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

16.0K

USD

Months

6-9

88.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 328.71% over the last month.

Sold

0-3

Months

3.3M

USD

3-6

Months

3.1M

USD

6-9

Months

6.8M

USD

0-12

Months

2.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LH News & Events

Events Timeline

2025-07-29 (ET)

2025-07-29

07:14:38

Labcorp achieves IVDR CE-Marking for PGDx elio tissue complete in the EU

2025-07-24 (ET)

2025-07-24

09:55:01

Early notable gainers among liquid option names on July 24th

2025-07-24

06:57:06

Labcorp raises FY25 adjusted EPS view to $16.05-$16.50 from $15.70-$16.40

News

5.0

07-30PRnewswire

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

9.0

07-29PRnewswire

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

4.0

07-25Benzinga

Evercore ISI Group Maintains Outperform on Labcorp Hldgs, Raises Price Target to $300

People Also Watch

LUV

Southwest Airlines Co

SS&C Technologies Holdings Inc

International Paper Co

Restaurant Brands International Inc

FAQ

What is Labcorp Holdings Inc (LH) stock price today?

The current price of LH is 267.67 USD — it has increased 0.68 % in the last trading day.

LH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Labcorp Holdings Inc (LH) stock price today?

What is Labcorp Holdings Inc (LH)'s business?

What is the price predicton of LH Stock?

What is Labcorp Holdings Inc (LH)'s revenue for the last quarter?

What is Labcorp Holdings Inc (LH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Labcorp Holdings Inc (LH)'s fundamentals?

How many employees does Labcorp Holdings Inc (LH). have?

What is Labcorp Holdings Inc (LH) market cap?